Open Access



Main Article Content

Samantha Lokelani Crossen
Tarun Goswami corresponding author


Drug delivery with nanoparticulate carriers is a new and upcoming research area that is making major changes within the pharmaceutical industry.  Nanoparticulate carriers are discussed, particularly, engineered nanoparticulate carriers used as drug delivery systems for targeted delivery. Nanoparticulate carriers that are used for drug delivery systems include polymers, micelles, dendrimers, liposomes, ceramics, metals, and various forms of biological materials.  The properties of these nanoparticulate carriers are very advantageous for targeted drug delivery and result in efficient drug accumulation at the targeted area of interest, reduced drug toxicity, reduced systemic side effects, and more efficient use of the drug overall.  Nanoparticlulate carriers are effective in passing various biological impediments and have a relatively high cellular uptake compared to that of microparticulate carriers, which allows for the drug agent to reach a targeted cell or tissue.  The use of nanoparticulate carriers for drug delivery results in a prolonged and sustained release of the drug which ultimately reduces the cost and amount of doses that need to be administered to the patient.  Currently, there is extensive research of nanoparticles as drug delivery carriers for challenging disease treatment cases such as cancer, HIV, and diabetes.

drug delivery, pharmaceutical, nanoparticulate carriers, nanoparticles, polymers

Article Details

How to Cite
Crossen, S. L., & Goswami, T. (2022). Nanoparticulate carriers for drug delivery. Journal of Pharmaceutical and Biopharmaceutical Research, 4(1), 237-247.


  1. Sahoo SK and Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discovery Today, 2003, 8: 1112-1120.
  2. Sahoo SK, Parveen S and Panda JJ. The Present and Future of Nanotechnology in Human Health Care. Nanomedicine, 2007, 3: 20-31.
  3. Hilt JZ and Peppas NA. Microfabricated drug delivery devices. International Journal of Pharmaceutics, 2005, 306: 15-23.
  4. Hasirci N. Micro and Nano Systems in Biomedicine and Drug Delivery. Nanomaterials and Nanosystems for Biomedical Applications, 2007, 1-26.
  5. Muller RH and Keck CM. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. Journal of Biotechnology, 2004, 113: 151-170.
  6. Kingsley JD, Dou H, Morehead J, et al. Nanotechnology: A Focus of Nanoparticles as a Drug Delivery System. Journal of Neuroimmune Pharmacology, 2006, 1: 340-350.
  7. Sahoo SK, Jain TK, Reddy MK, et al. Nano-Sized Carriers for Drug Delivery. NanoBioTechnology: BioInspired Devices and Materials of the Future, 2008, 329-348.
  8. Yih TC and Al-Fandi M. Engineered Nanoparticles as Precise Drug Delivery Systems. Journal of Cellular Biochemistry, 2006, 97: 1184-1190.
  9. Parveen S and Sahoo SK. Nanomedicine: Clinical Applications of Polyethylene Glycol Conjugated Proteins and Drugs. Clinical Pharmacokinetics, 2006, 45(10): 965-988.
  10. Salvage JP, Rose SF, Phillips GJ, et al. Novel biocompatible phosphorylcholine-based self-assembled nanoparticles for drug delivery. Journal of Controlled Release, 2005, 104: 259-270.
  11. Patel DN and Bailey SR. Nanotechnology in Cardiovascular Medicine. Catheterization and Cardiovascular Interventions, 2007, 69: 643-654.
  12. Gaumet M, Vargas A, Gurny V, et al. Nanoparticles for drug delivery: The need for precision in reporting particle size parameters. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69: 1-9.
  13. Lassalle V and Ferreira ML. PLA Nano- and Microparticles for Drug Delivery: An Overview of the Methods of Preparation. Macromolecular Bioscience, 2007, 7: 767-783.
  14. Popov C. Nanostructured Carbon Materials. Functional Properties of Nanostructured Materials, 2006, 387-398.
  15. Yokoyama M. Drug targeting with nano-sized carrier systems. International Journal of Artificial Organs, 2005, 8: 77-84.
  16. Torchilin VP. Micellar Nanocarriers: Pharmaceutical Perspectives. Pharmaceutical Research, 2007, 24: 1-16.
  17. Haley B and Frenkel E. Nanoparticles for drug delivery in cancer treatement. Urological Oncology, 2008, 26: 57-64.
  18. Moghimi SM, Hunter AC and Murray JC. Long-Circulating and Target-Specific Nanoparticles: Theory to Practice. Pharmacological Reviews, 2001, 53: 283-318.
  19. Wang X, Yang L, Chen Z, et al. Application of Nanotechnology in Cancer Therapy and Imaging. A Cancer Journal for Clinicians, 2008, 58: 97-110.
  20. Olivier JC. Drug Transport to Brain with Targeted Nanoparticles. The American Society for Experimental NeuroTherapeutics, 2005, 2: 108-119.
  21. Devalapally H, Chakilam A and Amiji MM. Role of Nanotechnology in Pharmaceutical Product Development. Journal of Pharmaceutical Sciences, 2006, 96(10): 2547-2565.
  22. Ganta S, Devalapally H, Shahiwala A, et al. A review of stimul-responsive nanocarriers for drug and gene delivery. Journal of Controlled Release, 2008, 126: 187-204.
  23. Panyam J and Labhasetwar V. Biodegradable nanoparticles for drug delivery gene delivery to cells and tissue. Advanced Drug Delivery Reviews, 2003, 55: 329-347.
  24. Koo OM, Rubinstein I and Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine: Nanotechnology, Biology, and Medicine, 2005, 1: 193-212.
  25. Hughes GA. Nanostructure-mediated drug delivery. Nanomedicine, 2005, 1: 22-30.
  26. Jones AT, Gumbleton M and Duncan R. Understanding endocytic pathways and intracellular trafficking: a prerequisite for effective design of advanced drug delivery systems. Advanced Drug Delivery Reviews, 2003, 55: 1353-1357.
  27. Watson P, Jones AT and Stephens DJ. Intracellular trafficking pathways and drug delivery: fluorescence imaging of living and fixed cells. Advanced Drug Delivery Reviews, 2005, 57: 43-61.
  28. Medina-Kauwe LK. “Alternative” endocytic mechanisms exploited by pathogens: New avenues for therapeutic delivery? Advanced Drug Delivery Reviews, 2007, 59: 798-809.
  29. Desai MP, Labhasetwar V, Amidon GL, et al. Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size. Pharmaceutical Research, 1996, 13(12): 1828-1845.
  30. Desai MP, Labhasetwar V,Walter E, et al. The Mechanism of Uptake of Biodegradable Microparticles in Caco-2 Cells Is Size Dependent. Pharmaceutical Research, 1997, 14(11): 1568-1573.
  31. Costa P and Lobo JMS. Modeling and comparison of dissolution profiles. European Journal of Pharmaceutical Sciences, 2001, 13: 123-133.
  32. Fahmy TM, Fong PM, Park J, et al. Nanosystems for Simultaneous Imaging and Drug Delivery to T Cells. The AAPS Journal, 2007, 9: 171-180.
  33. Lu Y and Chen SC. Micro and nano-fabrication of biodegradable polymers for drug delivery. Advanced Drug Delivery Reviews, 2004, 56: 1621-1633.
  34. Yoo HS and Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. Journal of Controlled Release, 2004, 96: 273-283.
  35. Lee CC, Mackay JA, Frechet JMJ, et al. Designing dendrimers for biological applications. Nature Biotechnology, 2005, 23: 1517-1526.
  36. Crampton HL and Simanek EE. Mini Review: Dendrimers as drug delivery vehicles: non-covalent interactions of bioactive compounds with dendrimers. Polymer International, 2007, 56: 489-496.
  37. Crommelin DJA, Bos GW and Storm G. Liposomes-Successful Carrier Systems for Targeted Delivery of Drugs. Business Briefing: Pharmatech, 2003, 209-213.
  38. Lian T and Ho RJY. Trends and Developments in Liposome Drug Delivery Systems. Journal of Pharmaceutical Sciences, 2001, 90(6): 667-680.
  39. Petrak K. Essential properties of drug-targeting delivery systems. Drug Discovery Today, 2005, 10: 1667-1673.
  40. Charcosset C, El-Harati A and Fessi H. Preparation of solid lipid nanoparticles using a membrane contractor. Journal of Controlled Release, 2005, 108: 112-120.
  41. Blasi P, Giovagnoli S, Schoubben A, et al. Solid lipid nanoparticles for targeted brain drug delivery. Advanced Drug Delivery Reviews, 2005, 59: 454-477.
  42. Wong HL, Bendayan R, Rauth AM, et al. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Advanced Drug Delivery Reviews, 2007, 59: 491-504.
  43. Nadarajan SB, Katsikis PD and Papazoglou ES. Loading carbon nanotubes with viscous fluids and nanoparticles-a simpler approach. Applied Physics A, 2007, 89: 437-442.
  44. Bianco A and Prato M. Can Carbon Nanotubes Be Considered Useful Tools for Biological Applications? Advanced Materials, 2003, 15: 1795-1768.
  45. Wang Y, Iqbal Z and Malhotra SV. Functionalization of carbon nanotubes with amines and enzymes. Chemical Physics Letters, 2005, 402: 96-101.
  46. Ma A, Lu J, Yang S, et al. Quantitative Non-Covalent Functionalization of Carbon Nanotubes. Journal of Cluster Science, 2006, 17: 599-608.
  47. Bhattacharya R and Mukherjee P. Biological properties of “naked” metal nanoparticles. Advanced Drug Delivery Reviews, 2008, 60: 1289-1306.
  48. Bhumkar DR, Joshi HM, Sastry M, et al. Chitosan Reduced Gold Nanoparticles as Novel Carriers for Transmucosal Delivery of Insulin. Pharmaceutical Research, 2007, 24(8): 1415-1426.